Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Health Technology Assessment

Volumn 14, Issue 4, 2010, Pages 1-331

  Mowatt, G ^a   Zhu, S ^a   Kilonzo, M ^b   Boachie, C ^a   Fraser, C ^a   Griffiths, T R L ^c   N'Dow, J ^b   Nabi, G ^b   Cook, J ^a   Vale, L ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; BCG VACCINE; BIOLOGICAL MARKER; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; HYPERICIN; METHOTREXATE; MITOMYCIN C; NUCLEAR MATRIX PROTEIN 22; VINBLASTINE;

BACTERIURIA; BLADDER BIOPSY; BLADDER CANCER; BLADDER CONTRACTION; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CYSTITIS; CYSTOSCOPY; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG HYPERSENSITIVITY; DYSURIA; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; MICROSCOPY; MICTURITION DISORDER; PHOTODYNAMICS; PHOTOSENSITIVITY; PHOTOTOXICITY; PREVALENCE; PROGNOSIS; RECURRENCE FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; URINE RETENTION; WHITE LIGHT MICROSCOPY;

COST-BENEFIT ANALYSIS; CYSTOSCOPY; DECISION SUPPORT TECHNIQUES; DIAGNOSTIC TECHNIQUES, UROLOGICAL; GREAT BRITAIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; MODELS, ECONOMIC; NUCLEAR PROTEINS; PHOTOSENSITIZING AGENTS; PREVALENCE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 76649099556     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta14040     Document Type: Review

References (216)

1. World Health Organization. International classificiation of diseases and related health problems (ICD) 10th revision. Geneva: World Health Organization; 2007. URL: www.who.int/classifications/apps/icd/icd10online/. Accesssed July 2008.
2. UroVysion fluorescence in situ hybridisation (FISH) assay. MSAC Application 1084. Canberra: Medical Services Advisory Committee; 2005. URL: www.msac.gov.au/internet/msac/publishing.nsf/Content/ 4753418A5C8F33DDCA25745E000A3933/$File/1084%20-%20UroVysion%20Report.pdf. Accesssed September 2008.
3. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou J. Guidelines on TaT1 (non-muscle-invasive) bladder cancer [document on the internet]. Arnhem: European Association of Urology; 2009 [accesssed May 2009]. URL: www.uroweb.org/fileadmin/tx-eauguidelines/2009/Full/TaT1-BC.pdf.
4. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
5. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Schellhammer PF, Seigne JD, et al. Guideline for the management of nonmuscle invasive bladder cancer: (stages Ta,T1 and Tis). 2007 update. Linthicum, MD: American Urological Association; 2007. URL: www.auanet.org/guidelines/bladcan07.cfm. Accesssed July 2008.
6. Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer 2000;86:289-94.
7. Brennan P, Bogillot O, Greiser E, Chang-Claude J, Wahrendorf J, Cordier S, et al. The contribution of cigarette smoking to bladder cancer in women (pooled European data). Cancer Causes Control 2001;12:411-7.
8. Occupational bladder cancer: a guide for clinicians. The BAUS Subcommittee on Industrial Bladder Cancer. Br J Urol 1988;61:183- 91.
9. Steinmaus CM, Nunez S, Smith AH. Diet and bladder cancer: a meta-analysis of six dietary variables. Am J Epidemiol 2000;151:693-702.
10. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol 2007;25:285-95.
11. Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll PR, et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 2007;177:883-7.
12. Duncan RE, Bennett DW, Evans AT, Aron BS, Schellhas HF. Radiation-induced bladder tumors. J Urol 1977;118:43-5.
13. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366:649-59.
14. Engel LS, Taioli E, Pfeiffer R, Garcia-Closas M, Marcus PM, Lan Q, et al. Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. Am J Epidemiol 2002;156:95-109.
15. Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, et al. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 1995;27:110-6.
16. Sobin DH, Witteking CH, editors. TNM classification of malignant tumours. 6th edn. New York: Wiley-Liss; 2002.
17. Mostofi FK. International histologic classification of tumors. A report by the Executive Committee of the International Council of Societies of Pathology. Cancer 1974;33:1480-4.
18. Harnden P. A critical appraisal of the classification of urothelial tumours: time for a review of the evidence and a radical change? BJU Int 2007;99:723-5.
19. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
20. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
21. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
22. Cancer Research UK. UK bladder cancer statistics. 2007. URL: http://info.cancerresearchuk.org/cancerstats/types/bladder/?a=5441. Accesssed July 2008.
23. Hayne D, Arya M, Quinn MJ, Babb PJ, Beacock CJ, Patel HR. Current trends in bladder cancer in England and Wales. J Urol 2004;172:1051-5.
24. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Bladder cancer including upper tract tumours and urothelial carcinoma of the prostate. V.2.2008. Fort Washington, PA: National Comprehensive Cancer Network; 2008. URL: www.nccn.org/professionals/ physician-gls/PDF/bladder.pdf. Accesssed July 2008.
25. Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int 2006;97:301-5.
26. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000;163:524-7.
27. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002;10:311-22.
28. BAUS Section of Oncology, British Uro-oncology Group (BUG). MDT (multi-disciplinary team) guidance for the managing of bladder cancer [document on the internet]. London: British Association of Urological Surgeons; 2007 [accesssed July 2008]. URL: www.bauslibrary.co.uk/PDFS/BSONC/ MDT%20guidance%20for%20bladder%20cancer.pdf.
29. Hall RR, et al. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ 1994;308:257-60.
30. Mead GM, Russell M, Clark P, Harland SJ, Harper PG, Cowan R, et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 1998;78:1067-75.
31. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15:2564-9.
32. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. The economic consequences of prostate and bladder cancer in the UK. BJU Int 2005;95:59-63.
33. Bosanquet N, Sikora K. The economics of cancer care in the UK. Lancet Oncol 2004;5:568-74.
34. Impoving outcomes in urological cancers. Guidance on cancer services: the manual. London: National Institute for Clinical Excellence; 2002. URL: www.nice.org.uk/nicemedia/pdf/Urological-Manual.pdf. Accesssed July 2008.
35. National Institute for Clinical Excellence. Laparoscopic cystectomy. Interventional procedures guidance IPG026. London: National Institute for Clinical Excellence; 2003. URL: www.nice.org.uk/nicemedia/pdf/ip/ipg026guidance. pdf. Accesssed July 2008.
36. Scottish Intercollegiate Guidelines Network. Management of transitional cell carcinoma of the bladder. SIGN Guideline No. 85. Edinburgh: Scottish Intercollegiate Guidelines Network; 2005. URL: www.sign.ac.uk/pdf/sign85.pdf. Accesssed July 2008.
37. National Institute for Health and Clinical Excellence. Intravesical microwave hyperthermia with intravesical chemotherapy for superficial bladder cancer. Interventional procedure guidance IPG235. London: National Institute for Health and Clinical Excellence; 2007. URL: www.nice.org.uk/Guidance/IPG235/ Guidance/pdf/English. Accesssed July 2008.
38. Foster M, Barnish L, Tudway D, Guest P, James N, McGarr C, et al. Guidelines for the management of bladder. Birmingham: NHS Pan-Birmingham Cancer Network; 2007. URL: www.birminghamcancer.nhs.uk/viewdoc.ashx?id= wORYwedcX6oZ1cEsM0xp6g%3d%3d. Accesssed July 2008.
39. National Screening Committee. Evaluation of urinary tract malignancy (bladder cancer) screening against NSC criteria. London: UK National Screening Committee; 2002. URL: www.library.nhs.uk/screening/ViewResource.aspx? resID=60477&tabID=288. Accesssed July 2008.
40. Stenzl A, Cowan NC, de Santis M, Jakse G, Kuczyk M, Merseburger MS, et al. Guideline on bladder cancer: muscle-invasive and metastatic [document on the internet]. Arnhem: European Association of Urology; 2009 [accesssed July 2008]. URL: www.uroweb.org/fileadmin/tx-eauguidelines/2009/Full/Muscle-Invasive- BC.pdf.
41. Lokeshwar VB, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66:35-63.
42. Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003;170:428-32.
43. Grossman HB, Blute ML, Dinney CP, Jones JS, Liou LS, Reuter VE, et al. The use of urine-based biomarkers in bladder cancer. Urology 2006;67:62-4.
44. Wazait HD, Al Bhueissi SZ, Patel HR, Nathan MS, Miller RA. Long-term surveillance of bladder tumours: current practice in the United Kingdom and Ireland. Eur Urol 2003;43:485-8.
45. Chahal R, Darshane A, Browning AJ, Sundaram SK. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder. Eur Urol 2001;40:415-20.
46. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003;3:25.
47. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:1235-41.
48. Macaskill P. Empirical Bayes estimates generated in a hierarchical summary ROC analysis agreed closely with those of a full Bayesian analysis. J Clin Epidemiol 2004;57:925-32.
49. Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 2001;20:2865-84.
50. Cheng CW, Lau WK, Tan PH, Olivo M. Cystoscopic diagnosis of bladder cancer by intravesical instillation of 5-aminolevulinic acid induced porphyrin fluorescence - the Singapore experience. Ann Acad Med Singapore 2000;29:153-8.
51. Colombo R, Naspro R, Bellinzoni P, Fabbri F, Guazzoni G, Scattoni V, et al. Photodynamic diagnosis for follow-up of carcinoma in situ of the bladder. Therap Clin Risk Manag 2007;3:1003-7.
52. D'Hallewin MA, De Witte PA, Waelkens E, Merlevede W, Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol 2000;164:349-51.
53. De Dominicis C, Liberti M, Perugia G, De Nunzio C, Sciobica F, Zuccala A, et al. Role of 5-aminolevulinic acid in the diagnosis and treatment of superficial bladder cancer: improvement in diagnostic sensitivity. Urology 2001;57:1059-62.
54. Ehsan A, Sommer F, Haupt G, Engelmann U. Significance of fluorescence cystoscopy for diagnosis of superficial bladder cancer after intravesical instillation of delta aminolevulinic acid. Urol Int 2001;67:298- 304.
55. Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. 5-aminolevulinic acid-induced fluorescence endoscopy applied at secondary transurethral resection after conventional resection of primary superficial bladder tumors. Urology 1999;53:77-81.
56. Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF. Clinical results of the transurethral resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol 1999;13:117-21.
57. Fradet Y, Grossman HB, Gomella L, Lerner S, Cookson M, Albala D, et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 2007;178:68-73.
58. Frimberger D, Zaak D, Stepp H, Knuchel R, Baumgartner R, Schneede P, et al. Autofluorescence imaging to optimize 5-ALA-induced fluorescence endoscopy of bladder carcinoma. Urology 2001;58:372-5.
59. Grimbergen MC, van Swol CF, Jonges TG, Boon TA, van Moorselaar RJ. Reduced specificity of 5-ALA induced fluorescence in photodynamic diagnosis of transitional cell carcinoma after previous intravesical therapy. Eur Urol 2003;44:51-6.
60. Hendricksen K, Moonen PM, der Heijden AG, Witjes JA. False-positive lesions detected by fluorescence cystoscopy: any association with p53 and p16 expression? World J Urol 2006;24:597-601.
61. Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, et al. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology 2007;69:260- 4.
62. Jeon SS, Kang I, Hong JH, Choi HY, Chai SE. Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms. J Endourol 2001;15:753-9.
63. Jichlinski P, Forrer M, Mizeret J, Glanzmann T, Braichotte D, Wagnieres G, et al. Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med 1997;20:402-8.
64. Jichlinski P, Wagnieres G, Forrer M, Mizeret J, Guillou L, Oswald M, et al. Clinical assessment of fluorescence cytoscopy during transurethral bladder resection in superficial bladder cancer. Urol Res 1997;25:S3-6.
65. Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer - a multicenter study. J Urol 2003;170:226-9.
66. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 2005;174:862-6.
67. Koenig F, McGovern FJ, Larne R, Enquist H, Schomacker KT, Deutsch TF. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 1999;83:129-35.
68. Kriegmair M, Baumgartner R, Knuechel R, Steinbach P, Ehsan A, Lumper W, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994;44:836-41.
69. Kriegmair M, Stepp H, Steinbach P, Lumper W, Ehsan A, Stepp HG, et al. Fluorescence cystoscopy following intravesical instillation of 5-aminolevulinic acid: a new procedure with high sensitivity for detection of hardly visible urothelial neoplasias. Urol Int 1995;55:190-6.
70. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol 1996;155:105-9.
71. Kriegmair M, Zaak D, Stepp H, Stepp H, Baumgartner R, Knuechel R, et al. Transurethral resection and surveillance of bladder cancer supported by 5-aminolevulinic acid-induced fluorescence endoscopy. Eur Urol 1999;36:386-92.
72. Landry JL, Gelet A, Bouvier R, Dubernard JM, Martin X, Colombel M. Detection of bladder dysplasia using 5-aminolaevulinic acid-induced porphyrin fluorescence. BJU Int 2003;91:623-6.
73. Riedl CR, Plas E, Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. J Endourol 1999;13:755-9.
74. Schneeweiss S, Kriegmair M, Stepp H. Is everything all right if nothing seems wrong? A simple method of assessing the diagnostic value of endoscopic procedures when a gold standard is absent. J Urol 1999;161:1116-9.
75. Schneeweiss S. Sensitivity analysis of the diagnostic value of endoscopies in cross-sectional studies in the absence of a gold standard. Int J Technol Assess Health Care 2000;16:834-41.
76. Sim HG, Lau WK, Olivo M, Tan PH, Cheng CW. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma? BJU Int 2005;95:1215-8.
77. Song X, Ye Z, Zhou S, Yang W, Zhang X, Liu J, et al. The application of 5-aminolevulinic acid-induced fluorescence for cystoscopic diagnosis and treatment of bladder carcinoma. Photodiagnosis Photodyn Ther 2007;4:39-43.
78. Szygula M, Wojciechowski B, Adamek M, Pietrusa A, Kawczyk-Krupka A, Cebula W, et al. Fluorescent diagnosis of urinary bladder cancer - a comparison of two diagnostic modalities. Photodiagnosis Photodyn Ther 2004;1:23-6.
79. Szygula M, Wojciechowski B, Adamek M, Kawczyk-Krupka A, Cebula W, Zieleznik W, et al. Photodynamic vs autofluorescent diagnosis of urinary bladder using Xillix LIFE system. Phys Med 2004;20:55-7.
80. Tritschler S, Scharf S, Karl A, Tilki D, Knuechel R, Hartmann A, et al. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis. Eur Urol 2007;51:403-7.
81. Witjes JA, Moonen PM, van der Heijden AG. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective Phase II study. Eur Urol 2005;47:319-22.
82. Zaak D, Kriegmair M, Stepp H, Stepp H, Baumgartner R, Oberneder R, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies. Urology 2001;57:690-4.
83. Zaak D, Hungerhuber E, Schneede P, Stepp H, Frimberger D, Corvin S, et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer 2002;95:1234-8.
84. Zaak D, Stepp H, Baumgartner R, Schneede P, Waidelich R, Frimberger D, et al. Ultraviolet-excited (308 nm) autofluorescence for bladder cancer detection. Urology 2002;60:1029-33.
85. Zumbraegel A, Bichler KH, Krause FS, Feil G, Nelde HJ. The photodynamic diagnosis (PDD) for early detection of carcinoma and dysplasia of the bladder. Adv Exp Med Biol 2003;539:61-6.
86. Babjuk M, Soukup V, Petrik R, Jirsa M, Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 2005;96:798-802.
87. Burger M, Zaak D, Stief CG, Filbeck T, Wieland WF, Roessler W, et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 2007;52:142-7.
88. Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 2005;174:2129-33.
89. Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 2007;69:675-9.
90. Denzinger S, Wieland WF, Otto W, Filbeck T, Knuechel R, Burger M. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 2008;101:566-9.
91. Filbeck T, Pichlmeier U, Knuechel R, Wieland WF, Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002;168:67-71.
92. Kriegmair M, Zaak D, Rothenberger KH, Rassweiler J, Jocham D, Eisenberger F, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002;168:475-8.
93. Riedl CR, Daniltchenko D, Koenig F, Simak R, Loening SA, Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001;165:1121-3.
94. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Freiberger A, et al. Combined morphologic and fluorescence in situ hybridization analysis of voided urine samples for the detection and follow-up of bladder cancer in patients with benign urine cytology. Cancer 2007;111:517-24.
95. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int 2003;92:911-4.
96. Friedrich MG, Hellstern A, Hautmann SH, Graefen M, Conrad S, Huland E, et al. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J Urol 2002;168:470-4.
97. Halling KC, King W, Sokolova IA, Meyer RG, Burkhardt HM, Halling AC, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164:1768- 75.
98. Junker K, Fritsch T, Hartmann A, Schulze W, Schubert J. Multicolor fluorescence in situ hybridization (M-FISH) on cells from urine for the detection of bladder cancer. Cytogenet Genome Res 2006;114:279-83.
99. Kipp BR, Halling KC, Campion MB, Wendel AJ, Karnes RJ, Zhang J, et al. Assessing the value of reflex fluorescence in situ hybridization testing in the diagnosis of bladder cancer when routine urine cytological examination is equivocal. J Urol 2008;179:1296-301.
100. Meiers I, Singh H, Hossain D, Lang K, Liu L, Qian JQ, et al. Improved filter method for urine sediment detection of urothelial carcinoma by fluorescence in situ hybridization. Arch Pathol Lab Med 2007;131:1574-7.
101. Mian C, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Lusuardi L, et al. Liquid-based cytology as a tool for the performance of uCyt+ and Urovysion Multicolour-FISH in the detection of urothelial carcinoma. Cytopathology 2003;14:338-42.
102. Moonen PM, Merkx GF, Peelen P, Karthaus HF, Smeets DF, Witjes JA. UroVysion compared with cytology and quantitative cytology in the surveillance of non-muscle invasive bladder cancer. Eur Urol 2007;51:1275-80.
103. Sarosdy MF, Kahn PR, Ziffer MD, Love WR, Barkin J, Abara EO, et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006;176:44-7.
104. Skacel M, Fahmy M, Brainard JA, Pettay JD, Biscotti CV, Liou LS, et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003;169:2101-5.
105. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000;2:116-23.
106. Yoder BJ, Skacel M, Hedgepeth R, Babineau D, Ulchaker JC, Liou LS, et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295-301.
107. May M, Hakenberg OW, Gunia S, Pohling P, Helke C, Lubbe L, et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 2007;70:449-53.
108. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950-4.
109. Lodde M, Mian C, Negri G, Berner L, Maffei N, Lusuardi L, et al. Role of uCyt+ in the detection and surveillance of urothelial carcinoma. Urology 2003;61:243-7.
110. Lodde M, Mian C, Comploj E, Palermo S, Longhi E, Marberger M, et al. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma. Urology 2006;67:950-4.
111. Messing EM, Teot L, Korman H, Underhill E, Barker E, Stork B, et al. Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United States. J Urol 2005;174:1238-41.
112. Mian C, Pycha A, Wiener H, Haitel A, Lodde M, Marberger M. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol 1999;161:1486-9.
113. Mian C, Maier K, Comploj E, Lodde M, Berner L, Lusuardi L, et al. uCyt+/ImmunoCyt in the detection of recurrent urothelial carcinoma: an update on 1991 analyses. Cancer 2006;108:60-5.
114. Olsson H, Zackrisson B. ImmunoCyt a useful method in the follow-up protocol for patients with urinary bladder carcinoma. Scand J Urol Nephrol 2001;35:280-2.
115. Pfister C, Chautard D, Devonec M, Perrin P, Chopin D, Rischmann P, et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J Urol 2003;169:921-4.
116. Piaton E, Daniel L, Verriele V, Dalifard I, Zimmermann U, Renaudin K, et al. Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study. Lab Invest 2003;83:845-52.
117. Schmitz-Drager BJ, Beiche B, Tirsar LA, Schmitz-Drager C, Bismarck E, Ebert T. Immunocytology in the assessment of patients with asymptomatic microhaematuria. Eur Urol 2007;51:1582-8.
118. Schmitz-Drager BJ, Tirsar LA, Schmitz-Drager C, Dorsam J, Mellan Z, Bismarck E, et al. Immunocytology in the assessment of patients with asymptomatic hematuria. World J Urol 2008;26:31-7.
119. Tetu B, Tiguert R, Harel F, Fradet Y. ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma. Mod Pathol 2005;18:83-9.
120. Bhuiyan J, Akhter J, O'Kane DJ. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder. Clin Chim Acta 2003;331:69-77.
121. Casella R, Huber P, Blochlinger A, Stoffel F, Dalquen P, Gasser TC, et al. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor. J Urol 2000;164:1926-8.
122. Casetta G, Gontero P, Zitella A, Pelucelli G, Formiconi A, Priolo G, et al. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder. Urol Int 2000;65:100-5.
123. Del Nero A, Esposito N, Curro A, Biasoni D, Montanari E, Mangiarotti B, et al. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test. Eur Urol 1999;35:93-7.
124. Giannopoulos A, Manousakas T, Mitropoulos D, Botsoli-Stergiou E, Constantinides C, Giannopoulou M, et al. Comparative evaluation of the BTA stat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors. Urology 2000;55:871-5.
125. Giannopoulos A, Manousakas T, Gounari A, Constantinides C, Choremi-Papadopoulou H, Dimopoulos C. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors [see comment]. J Urol 2001;166:470-5.
126. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-6.
127. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006;295:299-305.
128. Gutierrez Banos JL, Rebollo Rodrigo MH, Antolin Juarez FM, Martin GB. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study. Urol Int 2001;66:185-90.
129. Hughes JH, Katz RL, Rodriguez-Villanueva J, Kidd L, Dinney C, Grossman HB, et al. Urinary nuclear matrix protein 22 (NMP22): a diagnostic adjunct to urine cytologic examination for the detection of recurrent transitional-cell carcinoma of the bladder. Diagn Cytopathol 1999;20:285-90.
130. Kowalska M, Kaminska J, Kotowicz B, Fuksiewicz M, Rysinska A, Demkow T, et al. Evaluation of the urinary nuclear matrix protein (NMP22) as a tumour marker in bladder cancer patients. Nowotwory 2005;55:300-2.
131. Kumar A, Kumar R, Gupta NP. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006;36:172-5.
132. Lahme S, Bichler KH, Feil G, Krause S. Comparison of cytology and nuclear matrix protein 22 for the detection and follow-up of bladder cancer. Urol Int 2001;66:72-7.
133. Lahme S, Bichler KH, Feil G, Zumbragel A, Gotz T. Comparison of cytology and nuclear matrix protein 22 (NMP 22) for the detection and follow-up of bladder-cancer. Adv Exp Med Biol 2003;539:111-9.
134. Mian C, Lodde M, Haitel A, Vigl EE, Marberger M, Pycha A. Comparison of the monoclonal UBCELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder. Urology 2000;55:223-6.
135. Miyanaga N, Akaza H, Tsukamoto T, Ishikawa S, Noguchi R, Ohtani M, et al. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria. Int J Urol 1999;6:173-7.
136. Miyanaga N, Akaza H, Tsukamoto S, Shimazui T, Ohtani M, Ishikawa S, et al. Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection. Int J Clin Oncol 2003;8:369-73.
137. Oge O, Atsu N, Kendi S, Ozen H. Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer. Int Urol Nephrol 2001;32:367-70.
138. Oosterhuis JWA, Pauwels RPE, Schapers RFM, Van Pelt J, Smeets W, Newling DWW. Detection of recurrent transitional cell carcinoma of the bladder with nuclear matrix protein-22 in a follow-up setting. Urooncology 2002;2:137-42.
139. Ponsky LE, Sharma S, Pandrangi L, Kedia S, Nelson D, Agarwal A, et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J Urol 2001;166:75-8.
140. Poulakis V, Witzsch U, De Vries R, Altmannsberger HM, Manyak MJ, Becht E. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU Int 2001;88:692-701.
141. Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int 2002;89:369-73.
142. Sanchez-Carbayo M, Urrutia M, Gonzalez de Buitrago JM, Navajo JA. Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 2001;92:2820-8.
143. Serretta V, Lo PD, Vasile P, Gange E, Esposito E, Menozzi I. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 1998;52:793-6.
144. Serretta V, Pomara G, Rizzo I, Esposito E. Urinary BTA-stat, BTA-trak and NMP22 in surveillance after TUR of recurrent superficial transitional cell carcinoma of the bladder. Eur Urol 2000;38:419-25.
145. Shariat SF, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. J Urol 2003;170:2244-7.
146. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171:626-30.
147. Shariat SF, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Ludecke G, et al. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol 2006;176:919-26.
148. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53-7.
149. Stampfer DS, Carpinito GA, Rodriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998;159:394-8.
150. Talwar R, Sinha T, Karan SC, Doddamani D, Sandhu A, Sethi GS, et al. Voided urinary cytology in bladder cancer: is it time to review the indications? Urology 2007;70:267-71.
151. Wiener HG, Mian C, Haitel A, Pycha A, Schatzl G, Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1998;159:1876-80.
152. Zippe C, Pandrangi L, Potts JM, Kursh E, Novick A, Agarwal A. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer. Anticancer Res 1999;19:2621-3.
153. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999;161:62-5.
154. Abbate I, D'Introno A, Cardo G, Marano A, Addabbo L, Musci MD, et al. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. Anticancer Res 1998;18:3803-5.
155. Boman H, Hedelin H, Holmang S. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol 2002;167:80-3.
156. Chang YH, Wu CH, Lee YL, Huang PH, Kao YL, Shiau MY. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer. Urology 2004;64:687-92.
157. Lee KH. Evaluation of the NMP22 test and comparison with voided urine cytology in the detection of bladder cancer. Yonsei Med J 2001;42:14-8.
158. Parekattil SJ, Fisher HA, Kogan BA. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. J Urol 2003;169:917-20.
159. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, et al. Comparison of screening methods in the detection of bladder cancer. J Urol 1999;161:388-94.
160. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder. BJU Int 1999;84:706-13.
161. Sanchez-Carbayo M, Herrero E, Megias J, Mira A, Soria F. Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen, tissue polypeptide antigen, tissue polypeptide antigen and NMP22 to detect bladder cancer. J Urol 1999;162:1951-6.
162. Sanchez-Carbayo M, Urrutia M, Silva JM, Romani R, De Buitrago JM, Navajo JA. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer. J Urol 2001;165:1462-7.
163. Sozen S, Biri H, Sinik Z, Kupeli B, Alkibay T, Bozkirli I. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder. Eur Urol 1999;36:225-9.
164. Takeuchi Y, Sawada Y. A clinical study of urinary NMP22 in urinary epithelial cancer. J Med Soc Toho Univ 2004;51:332-8.
165. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer 1999;87:118-28.
166. Chahal R, Gogoi NK, Sundaram SK. Is it necessary to perform urine cytology in screening patients with haematuria? Eur Urol 2001;39:283-6.
167. Garbar C, Mascaux C, Wespes E. Is urinary tract cytology still useful for diagnosis of bladder carcinomas? A large series of 592 bladder washings using a five-category classification of different cytological diagnoses. Cytopathology 2007;18:79-83.
168. Hakenberg OW, Franke P, Froehner M, Manseck A, Wirth MP. The value of conventional urine cytology in the diagnosis of residual tumour after transurethral resection of bladder carcinomas. Onkologie 2000;23:252-7.
169. Hutterer GC, Karakiewicz PI, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, et al. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. BJU Int 2008;101:561-5.
170. Karakiewicz PI, Benayoun S, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, et al. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006;97:997-1001.
171. Planz B, Jochims E, Deix T, Caspers HP, Jakse G, Boecking A. The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol 2005;31:304-8.
172. Potter JM, Quigley M, Pengelly AW, Fawcett DP, Malone PR. The role of urine cytology in the assessment of lower urinary tract symptoms. BJU Int 1999;84:30-1.
173. Raitanen M-P, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 2002;41:284-9.
174. Raitanen MP, Aine RA, Kaasinen ES, Liukkonen TJ, Kylmala TM, Huhtala H, et al. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive? Scand J Urol Nephrol 2002;36:213-7.
175. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30.
176. Corwin HL, Silverstein MD. The diagnosis of neoplasia in patients with asymptomatic microscopic hematuria: a decision analysis. J Urol 1988;139:1002-6.
177. Ellwein LB, Farrow GM. Urinary cytology screening: the decision facing the asymptomatic patient. Med Decis Making 1988;8:110-9.
178. Novicki DE, Stern JA, Nemec R, Lidner TK. Costeffective evaluation of indeterminate urinary cytology. J Urol 1998;160:734-6.
179. Rodgers M, Nixon J, Hempel S, Aho T, Kelly J, Neal D, et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation. Health Technol Assess 2006;10(18).
180. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? A cost per life-year saved analysis. Cancer 2006;107:982-90.
181. Kurth KH, Denis L, Bouffioux C, Sylvester R, Debruyne FMJ, Pavone-Macaluso M, et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995;31:1840-6.
182. Dalesio O, Schulman CC, Sylvester R, De Pauw M, Robinson M, Denis L, et al. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 1983;129:730-3.
183. García RJ, Fernandez Gomez JM, Escaf BS, Jalon MA, Alvarez MM, Regadera SJ. [Pronostic factors on recurrence and progression of superficial bladder cancer. Risk groups (part II)]. Actas Urol Esp 2006;30:1009-16.
184. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150:60-4.
185. Kiemeney LA, Witjes JA, Heijbroek RP, Debruyne FM, Verbeek AL. Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer. Eur J Cancer 1994;30A:1621-5.
186. Loening S, Narayana A, Yoder L, Slymen D, Penick G, Culp D. Analysis of bladder tumor recurrence in 178 patients. Urology 1980;16:137-41.
187. Millán-Rodriguez F, Chéchile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000;164:680-4.
188. Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group. Br J Urol 1994;73:403-8.
189. Narayana AS, Loening SA, Slymen DJ, Culp DA. Bladder cancer: factors affecting survival. J Urol 1983;130:56-60.
190. Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stockle M, Sternberg CO. Guidelines on bladder cancer. Arnhem: European Association of Urology; 2001. URL: www.uroweb.org/fileadmin/tx-eauguidelines/2001-Bladder%20-Cancer.PDF. Accesssed September 2008.
191. Parmar H, Charlton C, Phillips RH, Lightman SL. Management of advanced prostatic cancer. Lancet 1989;2:1338-9.
192. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, Van der MA, Parmar MK, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996;156:1934-40.
193. Shinka T, Matsumoto M, Ogura H, Hirano A, Ohkawa T. Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guerin: a long-term follow-up. Int J Urol 1997;4:139-43.
194. Witjes JA, Kiemeney LALM, Verbeek ALM, Heijbroek RP, Debruyne FMJ. Random bladder biopsies and the risk of recurrent superficial bladder cancer: a prospective study in 1026 patients. World J Urol 1992;10:231-4.
195. Witjes JA, Kiemeney LA, Schaafsma HE, Debruyn FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urological Group. Br J Urol 1994;73:172-6.
196. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 1997;15:84-8.
197. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng A-C, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
198. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8.
199. Government Actuary's Department. Interim life tables 2004-6. London: Government Actuary's Department; 2008. URL: www.gad.gov.uk/ Demography%5FData/Life-Tables/Interim-life-tables.asp. Accesssed September 2008.
200. Farrow SC, Fowkes FGR, Lunn JN. Epidemiology in anaesthesia. II. Factors affecting mortality in hospital. Br J Anaesth 1982;54:811-7.
201. Kondas J, Szentgyorgyi E. Transurethral resection of 1250 bladder tumours. Int Urol Nephrol 1992;24:35-42.
202. Department of Health. NHS reference costs 2005-6. 2006. URL: www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-062884. Accesssed September 2008.
203. Tumour-marker NMP22 (NMP). Nottingham: MediChecks.com; 2008. URL: http://medichecks.com/index.cfm?s=2&d=21&test=NMP. Accesssed September 2008.
204. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute for Health and Clinical Excellence; 2008. URL: www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf. Accesssed September 2008.
205. Kulkarni GS, Finelli A, Fleshner NE, Jewett MAS, Lopushinsky SR, Alibhai SMH. Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med 2007;4:1538-49.
206. Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes 2007;5:70.
207. Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004;171:135-8.
208. Spiess PE, Grossman HB. Fluorescence cystoscopy: is it ready for use in routine clinical practice? Curr Opin Urol 2006;16:372-6.
209. Zaak D, Karl A, Knuchel R, Stepp H, Hartmann A, Reich O, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int 2005;96:217-22.
210. Jain S, Kockelbergh RC. The role of photodynamic diagnosis in the contemporary management of superficial bladder cancer. BJU Int 2005;96:17-21.
211. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003;61:109-18.
212. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003;169:1975-82.
213. van Rhijn BW, van der Poel HG, van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47:736-48.
214. Yossepowitch O, Herr HW, Donat SM. Use of urinary biomarkers for bladder cancer surveillance: patient perspectives. J Urol 2007;177:1277- 82.
215. Kiemeney LALM, Witjes JA, Heijbroek RP, Koper NP, Verbeek ALM, Debruyne FMJ. Should random urothelial biopsies be taken from patients with primary superficial bladder cancer? A decision analysis. Br J Urol 1994;73:164-71.
216. van der Meijden A, Oosterlinck W, Brausi M, Kurth K-H, Sylvester R, de Balincourt C. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC genito-urinary tract cancer cooperative group. Eur Urol 1999;35:267-71.